Semax is a synthetic peptide developed on the basis of a fragment of adrenocorticotropic hormone (ACTH), but without hormonal activity. It was originally created in Russia and is studied primarily in the fields of neuroscience, cognitive function, and brain protection.

Scientific interest in Semax is linked to its influence on brain signaling, neuronal plasticity, and the nervous system's adaptation under conditions of stress and mental demand.

The effects described below are based on published scientific studies and experimental models, primarily in the field of neuroscience.

Support for memory and learning: Semax is studied for its capacity to support processes related to memorization, assimilation of new information, and mental clarity.

Improved concentration and focus: Data from experimental models show that the peptide may support attention and sustained concentration under conditions of mental demand.

Protection of nerve cells: Semax is of interest due to its capacity to support the protection of nerve cells against various stress factors and aggression.

Regulation of the stress response: Studies suggest that the peptide may participate in balancing reactions to mental and physiological stress, without producing a sedative effect.

Improved adaptation and brain plasticity: Semax is associated with stimulation of processes that support brain adaptation and efficient communication between neurons.

Support for cognitive function under conditions of fatigue: In a research context, it is viewed as a means of maintaining mental performance under conditions of prolonged demand or mental fatigue.

Scientific standards require a precise approach to establishing amounts, for objectivity and reproducibility of results. In practice, the most common indicative research schemes are as follows:

More moderate approach: 200-300 mcg once per day — used as a baseline scheme in the initial observation of tolerability and the general cognitive/neuromodulatory effect.

More widespread approach: 250 mcg twice per day (morning and early afternoon), or a total of 500 mcg per day — this scheme is most frequently encountered in protocols for focus, memory, and adaptation to mental demand.

Duration: cycles most frequently range between 10 and 30 days, and in longer schemes a break of 1-2 weeks is often taken before a possible repeat, in order to preserve clarity of observations.

There is a clinical study indexed in MEDLINE/Europe PMC (Gusev et al., 1997) that analyzes Semax in patients during the acute period of ischemic stroke. The study follows neurological indicators and recovery, and the authors describe that Semax was associated with a more favorable dynamics of symptoms compared with standard observation within the research protocol.

There are experimental data published in Molecular Biology Reports (Medvedeva et al., 2014) in which Semax was studied in a model of cerebral ischemia (pMCAO), with an emphasis on changes in gene expression in the hours after injury. The authors show that Semax influences groups of genes associated not only with nervous tissue, but also with immune and vascular processes, which supports the idea of a "complex" neuroprotective profile under preclinical conditions.

There are studies that analyze Semax through the lens of neurotrophins — molecules important for brain plasticity and adaptation. In a publication indexed in PubMed (Dolotov et al., 2006), the authors discuss data according to which Semax may modulate the BDNF/TrkB system in brain structures, this being one of the most frequently mentioned biological lines associated with its cognitive effects.

There are also scientific review-type publications (for example, Acta Naturae, Radchenko et al., 2025) that bring together data on Semax and its derivatives — including preclinical results and limited clinical observations in various directions. These reviews emphasize that the best-represented clinical direction is in neurological conditions.

Semax is a synthetic peptide created as an analog of a fragment of adrenocorticotropic hormone (ACTH), but without hormonal activity. Its action is oriented primarily toward the central nervous system and is carried out through several clearly described biochemical and neuronal mechanisms.

Modulation of neurotransmitter systems: Semax influences the balance of key neurotransmitters such as dopamine, serotonin, and glutamate, which is linked to the cognitive and adaptive functions of the brain.

Regulation of BDNF and other neurotrophic factors: The peptide stimulates expression of brain-derived neurotrophic factor (BDNF), which plays a key role in neuronal plasticity, survival of nerve cells, and communication between neurons.

Influence on pathways associated with NMDA and AMPA receptors: Semax indirectly modulates the activity of receptors involved in synaptic plasticity and learning and memory processes, without acting as a direct agonist.

Antioxidant and anti-inflammatory signals: In experimental models, activation of intracellular pathways that reduce oxidative stress and inflammatory reactions in nervous tissue is observed.

Regulation of gene expression: Semax influences the expression of genes associated with the brain's adaptive response to stress, hypoxia, and ischemic conditions.

Available information on Semax is based primarily on research observations and published scientific data. As with any peptide, reactions may be individual and are generally mild and transient, without a long-lasting character.

Mild headache at the beginning of administration.

Transient sensation of increased mental activity or alertness.

Mild irritability or tension at higher doses.

Transient changes in sleep quality.

Mild discomfort at the administration site.

Most of these effects usually resolve spontaneously with adaptation or after dosage adjustment. In the scientific literature, Semax is viewed as a peptide with a good tolerability profile when used within reasonable, controlled research schemes.

Semax is frequently analyzed in the context of peptides that influence brain activity, cognitive functions, and adaptation to stress. Although some of these overlap as a "nootropic" profile, the differences in mechanism and focus are significant.

Semax versus Selank: The main difference lies in the direction of action. Selank is more strongly associated with a calming and anxiolytic profile, while Semax is more frequently associated with focus, memory, and mental clarity. For this reason, Semax is usually preferred in cognitive protocols and under mental demand, and Selank — in tension and anxiety.

Semax versus P21: P21 is analyzed more frequently in the context of neuroregeneration and structural support of nervous tissue, while Semax focuses on the functional activity of the brain — memory, attention, and adaptation to stress. Semax is used more frequently in functional and cognitive models, and P21 — in injury models.

What sets Semax apart from other nootropic peptides?

Semax is a peptide with neuromodulatory action, studied for its influence on memory, concentration, and adaptation to stress, without acting as a classic stimulant.

Is Semax suitable for prolonged research protocols?

In the scientific literature, Semax is often analyzed within cyclic protocols, with emphasis on the importance of breaks between cycles for objective observation of effects.

Does Semax influence energy and nervous excitation?

Semax is not associated with a sudden increase in excitation or with "overloading" of the nervous system, which sets it apart from stimulant nootropics such as caffeine or amphetamine derivatives.

How quickly are effects observed in research use?

In various research models, a relatively rapid functional response is reported, and in some protocols changes are observed within days, not weeks.

Can Semax be combined with other peptides?

In a research setting, Semax is often analyzed in combination with other neuropeptides when a broader effect on cognitive and adaptive processes is sought, with the approach usually being individual.